The pathology results from the biopsies obtained from the breast mass, as well as from the axillary and supraclavicular lymph nodes, all collectively confirmed the presence of invasive carcinoma characterized by estrogen receptor negative, progesterone receptor positive, and HER2 positive (ER−PR+HER2+), highlighting the critical role of molecular testing in guiding targeted treatment decisions, predicting therapy response, and facilitating personalized medicine. The gene discussed is ERBB2; the disease is invasive carcinoma.